Happy Festivus! Cost Curve Readers Have Some Grievances They’d Like to Air.

And a critical 2026 trend -- dropping list prices on blockbuster drugs -- has begun with a 40%+ cut to Imbruvica’s price

Christmas Comes Early for the Wonks, With CMS Demonstrations and MFN Announcements

And the results of the “Nobody Knows” Prediction Contest

The Number of Companies Set to Make MFN Announcements Today Is Up to At Least Six

Plus, a rosy AARP survey suggests that Medicare “negotiations” will lower out-of-pocket costs. The truth is likely to be more complicated.

Novartis, Roche, AbbVie Reportedly on Deck for White House MFN Announcements Tomorrow

And introducing the first annual ‘Nobody Knows’ Prediction Contest

Please Celebrate Festivus With Cost Curve by Airing Your Grievances

And Pfizer’s take on the pharm-to-table opportunity in obesity: ‘Multiples of what we were expecting’

Arnold Ventures' 2024 Grant Awards Are Now Public. Here’s What Those Dollars Say About the Group's Goals

And Pfizer offers few new details on how the MFN deal will impact the company’s bottom line next year

Big Companies Are Far Less Likely to Disclose Drug Prices Than Smaller Ones, New Study Shows

My research with Tufts CEVR on drug-price announcements, published today in AJMC, assessed 150 meds over three years

Sales at 340B Prices Continue to Skyrocket -- Jumping to More than $81 Billion -- Even as Questions Remain About Where the Money Goes

And a Tufts CEVR analysis suggests that cost-effectiveness is not playing a meaningful role in government price-setting efforts

A New Tracker for Watching Meds That Might See Prices Slashed

And an evolving list of all of the pricing and policy fun to be had between now and Christmas

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

And the 340B rebate model debate is coming to Cost Curve’s home turf: Portland

Reimbursement for Hep B Shots Should Remain Stable Even as CDC Panel Undermines the Vaccine

And a STAT analysis suggests that major health insurers are seeing med spending skyrocket, but a closer look at the data raises questions

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

And lawmaker talk of PBM reform has returned. Will action follow?

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

And doing the math on 340B rebate models suggests that pharma’s new approach to paying 340B discounts shouldn’t harm providers

The Need-to-Know on a Slow News Day: More MFN Deals Are Coming, and Why Pharma Thinks the U.S./U.K. Trade Agreement Should Be a Model

The U.K. Will Make Efforts to Boost Drug Prices in Return for the Elimination of U.S. Tariffs

And the pharm-to-table pricing of obesity medicines gets even more dizzying as Lilly cuts the price of Zepbound vials

The Search for Clarity on the Differences Between IRA and MFN Prices for Ozempic and Wegovy

And an FDA official calls out ‘unique financial incentives for vaccine makers’

Medicare Negotiated Prices Are Out for 15 More Drugs. Here’s What We Know

Today Is Mostly a Day for Waiting

Still, links to ponder on CMS hospital payments, the price of gene therapies, and UK price negotiations

The Universe of Direct-to-Business Obesity Options Continues to Expand

And more 340B stories than you can shake a stick at

The Pharm-to-Conference-Table Trend Is Picking Up Steam

And a CMS advisor offers a peek behind the curtain on the agency’s myriad drug-pricing workstreams

When Will CMS Publish the Next Set of ‘Negotiated’ Prices for Medicare?

And could states create a “Netflix” model to balance obesity-med spending and access?

Why a New Drug Just Entered the Market With a List Price One-Tenth of Its Rival

And a Health Affairs Forefront piece brings much-needed clarity to the 340B rebate model conversation

The Five Most Interesting Things Lilly’s Dave Ricks Said on the Cheeky Pint Pod

Drugmakers and the government argue 340B rebate models in federal appeals court

The Obesity Pricing Paradigm Gets Even More Complex With Novo’s $199 Wegovy Offer

And a ranked list of a dozen other stories from the past 96 hours

CMS Is About to Announce ‘Negotiated’ Prices on 15 More Medicines. Here’s What the Companies Involved Have Said About Those Prices